Ispinesib

Generic Name: Ispinesib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₃₀H_₃₃ClN_₄O_₂

CAS Number: 336113-53-2

Unique Ingredient Identifier: BKT5F9C2NI

Indication: Investigated for use/treatment in breast cancer, lung cancer, solid tumors, renal cell carcinoma, pediatric indications, ovarian cancer, and head and neck cancer.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study of Ispinesib in Metastatic Breast Cancer

Phase 1

Terminated

Conditions: Breast Neoplasms

Interventions: Drug: Ispinesib

First Posted Date: 2008-02-06

Last Posted Date: 2019-05-06

Lead Sponsor: Cytokinetics

Target Recruit Count: 16

Registration Number: NCT00607841

Locations: 🇵🇪
Hospital Nacional Alberto Sabogal Sologúren, Lima, Peru
🇵🇪
Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
🇵🇪
Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru

Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: Childhood Burkitt Lymphoma
Childhood Central Nervous System Germ Cell Tumor
Childhood Choroid Plexus Tumor
Childhood Craniopharyngioma
Childhood Grade I Meningioma
Childhood Grade II Meningioma
Childhood Grade III Meningioma
Childhood High-grade Cerebral Astrocytoma
Childhood Infratentorial Ependymoma
Childhood Low-grade Cerebral Astrocytoma

Interventions: Drug: ispinesib
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2006-08-15

Last Posted Date: 2013-01-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00363272

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer

Phase 2

Completed

Conditions: Recurrent Renal Cell Cancer
Stage III Renal Cell Cancer
Stage IV Renal Cell Cancer

Interventions: Drug: ispinesib

First Posted Date: 2006-07-20

Last Posted Date: 2013-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00354250

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Ispinesib In Combination With Capecitabine In Patients With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor Cancer

First Posted Date: 2005-07-13

Last Posted Date: 2008-10-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 30

Registration Number: NCT00119171

Locations: 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States

SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Recurrent Colon Cancer
Stage IIIA Rectal Cancer
Stage IIIB Rectal Cancer
Stage IIIC Rectal Cancer
Stage IVA Colon Cancer
Recurrent Rectal Cancer
Stage IIIC Colon Cancer
Stage IIIA Colon Cancer
Stage IIIB Colon Cancer
Stage IVA Rectal Cancer

Interventions: Drug: ispinesib
Other: laboratory biomarker analysis

First Posted Date: 2005-02-08

Last Posted Date: 2015-03-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 64

Registration Number: NCT00103311

Locations: 🇺🇸
University of Southern California, Norris, Los Angeles, California, United States

SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma

Phase 1

Terminated

Conditions: Adult Grade III Lymphomatoid Granulomatosis
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Grade III Lymphomatoid Granulomatosis
Recurrent Adult Hodgkin Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma

Interventions: Drug: ispinesib
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2005-01-10

Last Posted Date: 2013-01-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 31

Registration Number: NCT00101244

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes

Phase 1

Completed

Conditions: Acute Undifferentiated Leukemia
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)

Interventions: Drug: ispinesib
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2004-12-09

Last Posted Date: 2013-01-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00098826

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

First Posted Date: 2004-11-24

Last Posted Date: 2010-10-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 35

Registration Number: NCT00097409

Locations: 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States

SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel

Phase 2

Completed

Conditions: Recurrent Prostate Cancer
Stage IV Prostate Cancer
Adenocarcinoma of the Prostate

Interventions: Drug: ispinesib
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2004-11-10

Last Posted Date: 2013-01-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00096499

Locations: 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States

SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2004-11-09

Last Posted Date: 2013-05-17

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 17

Registration Number: NCT00095953

Locations: 🇨🇦
Fraser Valley Cancer Centre at British Columbia Cancer Agency, Surrey, British Columbia, Canada
🇨🇦
British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦
Toronto Sunnybrook Regional Cancer Centre at Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy